IDiyas

For the Inventor, By the Inventor

Budapest, Hungary

Erik Bogsch

USPTO Granted Patents = 14

Average Co-Inventor Count = 10.0

ph-index = 5

Forward Citations = 74(Granted Patents)


Company Filing History:

goldMedal14 out of 346 
 
Richter Gedeon Vegyeszeti Gyar Rt
 patents

Years Active: 1982-1992

Loading Chart...
14 patents (USPTO):Explore Patents
1. 5128477 - Process for the preparation of morphologically homogeneous forms of (1992-07-07),
2. 5120850 - Process for the preparation of morphologically homogeneous forms of (1992-06-09),
3. 4960888 - Preparation of (1990-10-02),
4. 4894459 - Process for the preparation of morphologically homogeneous forms of (1990-01-16),
5. 4835281 - Process for the preparation of (1989-05-30),
6. 4831194 - Process for the preparation of nitrodiaryl sulfoxides (1989-05-16),
7. 4816587 - Process for the preparation of 2-halogenated ergoline derivatives (1989-03-28),
8. 4780537 - Pyrimidine derivatives and process preparing the same (1988-10-25),
9. 4753949 - 2-chloronicergoline having antihypoxic activity (1988-06-28),
10. 4731479 - N-sulfamyl-3-halopropionamidines (1988-03-15),
11. 4710323 - Nitrodiaryl sulfoxide derivatives, process for their preparation and (1987-12-01),
12. 4697017 - Process for the preparation of 2-bromo-.alpha.-ergocryptine (1987-09-29),
13. 4681887 - Pharmaceutical compositions with a neuroleptic action and process for (1987-07-21),
14. 4334910 - Plant-protective and pest-control agent (1982-06-15),

Title: The Innovative Contributions of Erik Bogsch in Pharmaceutical Development

Introduction

Erik Bogsch, based in Budapest, Hungary, is a distinguished inventor known for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 14 patents, he has focused primarily on the formulation and preparation of drugs that enhance their efficacy and stability.

Latest Patents

Among his latest innovations are processes for the preparation of morphologically homogeneous forms of Famotidine, identified by its chemical name: N-sulfamoyl-3-(2-guanidino-thiazole-4-yl-methylthio)-propionamidine. This invention outlines methods of achieving these forms through selective crystallization or precipitation, thereby optimizing the drug's performance and usability.

Career Highlights

Erik Bogsch's career has been marked by his work at Richter Gedeon Vegyeszeti Gyar Rt., a leading pharmaceutical company in Hungary. His expertise in drug formulation has been instrumental in the development of several successful pharmaceutical products that cater to a variety of medical needs.

Collaborations

Throughout his career, Bogsch has collaborated with talented colleagues such as Bela Stefko and Ferenc Trischler, with whom he has shared insights and discoveries. These collaborations have fostered an environment of innovation and have further propelled advancements in pharmaceutical sciences.

Conclusion

Erik Bogsch's inventive spirit and commitment to pharmaceutical innovation underscore the importance of research and development in medicine. His contributions, particularly in the realm of drug formulation, continue to have a meaningful impact on improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…